England’s drug price regulator will have to reconsider its decision to rule out using Eli Lilly’s Alzheimer’s drug in the state-run National Health Service, following a successful appeal by the US drugmaker https://t.co/fWXon8Qsap ...

Financial Performance - Biogen raised its full-year financial guidance [1] - The company beat Wall Street's expectations [1] Product Performance - Growing sales of Biogen's Alzheimer's drug contributed to the positive financial results [1]